MPS Pharmaa Peer Comparison

In the Pharmaceuticals & Drugs sector, MPS Pharmaa Ltd. shows significant underperformance compared to its peers, characterized by zero growth metrics and negative valuation ratios. However, companies like Sun Pharmaceutical and Cipla stand out with strong profitability and growth, while others like Divi's Laboratories show high valuations despite weak revenue growth. MPS Pharmaa Ltd. is positioned as a value pick due to its low market price but lacks profitability and growth metrics.

• • MPS Pharmaa Ltd. exhibits no revenue growth and negative PE ratio, indicating severe financial distress.
• • Sun Pharmaceutical showcases the highest revenue growth (YoY: 8.42%) and strong profitability metrics (ROE: 16.13%).
• • Divi's Laboratories has the highest PE ratio (73.20) indicating overvaluation despite decent margins.

• • Sun Pharmaceutical Industries Ltd.: Highest revenue growth (YoY: 8.42%) and strong ROE (16.13%) with manageable debt.
• • Cipla Ltd.: Strong profitability (ROE: 16.63%) and good revenue growth (YoY: 13.28%) with low PEG ratio (0.35).